<?xml version="1.0" encoding="UTF-8"?>
<ref id="jmv25961-bib-0004">
 <label>4</label>
 <mixed-citation publication-type="miscellaneous" id="jmv25961-cit-0004">
  <collab collab-type="authors">Food and Drug Administration</collab> . 
  <article-title>Recommendations for Investigational COVID‚Äê19 Convalescent Plasma, Content current as of: 04/13/2020</article-title>. 
  <ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma</ext-link>. Accessed April 18, 2020.
 </mixed-citation>
</ref>
